Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

L. Gilman, Andrew; Fevzi Özkaynak, M.; K. Matthay, Katherine; Krailo, Mark; L. Yu, Alice; Gan, Jacek; Sternberg, Adam; A. Hank, Jacquelyn; C. Seeger, Robert; H. Reaman, Gregory; M. Sondel, Paul

doi:10.1200/jco.2006.10.3564

Public

Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

Published in Journal of Clinical Oncology • Dec 2, 2008

Authors:

Andrew L. Gilman

M. Fevzi Özkaynak

Katherine K. Matthay

Abstract

PURPOSE: Recurrence of high-risk neuroblastoma is common despite multimodality therapy. ch14.18, a chimeric human/murine anti-G(D2) antibody, lyses neuroblastoma cells. This study determined the maximum tolerable dose (MTD) and toxicity of ch14.18 given in combination with interleukin-2 (IL-2) after...

Subject

Medicine

Granulocyte colony-stimulating factor

Granulocyte macrophage colony-stimulating factor

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!